Abstract. The present study investigated the effects and mechanism by which curcumin suppresses intestinal microvascular endothelial cells (INMECs) invasion and angiogenesis induced by activated platelets. INMECs were obtained from healthy rats, and divided into five groups: Control, platelets, platelets +2.5 µM curcumin, platelets +5.0 µM curcumin and platelets +10.0 µM curcumin. Curcumin toxicity was determined and vascular endothelial growth factor (VEGF) concentrations of the five groups were measured using ELISA. The branch point numbers were measured using a capillary tube formation experiment, invasion cell numbers were evaluated with the Transwell assay, relative protein expression levels were measured with western blot assay and immunofluorescence staining of the nucleus. The 2.5, 5 and 10 µM curcumin concentrations were found to be suitable for INMECs. Curcumin significantly downregulated VEGF concentration, suppressed vascular lumen formation and inhibited invasion cell numbers in a dose-dependent manner. The α-smooth muscle actin, collagen I, E-cadherin, phosphorylated (p-) phosphoinositide 3-kinase (PI3K), p-protein kinase B (AKT), p-mammalian target of rapamycin (m-TOR) and hypoxia inducible factor subunit alpha (HIF-1α) protein expression levels of the curcumin-treated groups were significantly downregulated in a dose-dependent manner compared with the platelet group. HIF-1α protein expression levels in the nucleus of the curcumin-treated groups were significantly suppressed in a dose-dependent manner compared with the platelet group. In conclusion, curcumin suppressed INMEC invasion and angiogenesis induced by activated platelets via inhibiting the activation of the PI3K/AKT/mTOR pathway.
Introduction
Crohn's Disease (CD) is a chronic recurrent inflammatory disease affecting the digestive tract. The aetiology and pathogenesis of CD remains not fully understood. However, the consensus is that intestinal mucosal immune regulation, lymphangiogenesis and intestinal mucosal barrier damage are involved in the development of CD (1, 2) . A crucial area of current research has been the identification of effective drug components for CD treatment. Curcumin, one of the most popular traditional medicines, is a natural phenolic substance extracted from the rhizome of Curcuma longa. It has widely been used as a traditional herb in China and Southeast Asian countries for thousands of years. Recent studies have confirmed that curcumin possesses several pharmacological properties including antioxidant, anti-inflammatory and antitumour abilities; it also promotes wound healing, is spasmodic, serves as an anticoagulant and provides liver protection (3) (4) (5) . Several clinical and animal experiments have reported that curcumin has beneficial therapeutic effects on inflammatory bowel disease with few adverse effects. Therefore, curcumin possesses substantial potential for clinical application (6) (7) (8) (9) ; however the effects and mechanism of curcumin in CD treatment remain unclear. The present study determined suitable curcumin concentrations for further experimentation in cells using MTT assay. Then the effects of curcumin on suppressing angiogenesis and cell invasion were determined. Finally, the mechanisms by which curcumin can be used to treat CD were investigated by measuring relative protein expression levels using western blot analysis and immunofluorescence staining. INMEC isolation and culture. INMECs were isolated following the methods described in a previous review (10) . INMECs, at fourth or fifth passage, were cultured in the RPM 11650 culture medium containing 10% FBS and used for the following experiments.
Materials and methods

Experimental
MTT assay. Cells in the logarithmic growth phase were inoculated in a 96-well plate and routinely cultured until cell adherence was observed. Curcumin solution at concentrations of 0, 0.625, 1.25, 2.5, 5, 10, 20 and 40 µM were added to the samples for 4 h. Then the supernatant was removed and 200 µl dimethyl sulfoxide was added to each well. The samples were placed on a rocking bed at low-speed oscillation for 1 min. The absorbance values were measured at 490 nm wavelength and the cell viability of the different groups was measured. The experiment was repeated three times.
Cell grouping. According to the MTT assay result, INMECs were randomly divided into the following groups: Control, platelets and three different concentrations of curcumin-treated groups (2.5, 5 and 10 µM). The INMECs were cultured at a density of 1x10 4 cells/well for 4 h. The supernantants of the different groups were collected following centrifugation to measure VEGF concentrations then cells were collected for further experiments. The experiment was repeated three times.
ELISA. INMECs were treated with 25 µM ADP for 24 h at room temperature, followed by the curcumin treatment of various concentrations. Culture medium was collected and centrifuged at 10,000 x g for 5 min at 4˚C. The VEGF concentrations of the groups were measured with an ELISA kit at 490 nm according to the supplier's instructions. Each group was assigned nine wells.
Capillary tube formation experiment. Matrigel matrix glue was added to a 48-well culture plate at 37˚C for 30 min. INMECs were added to wells at a density of 1x10 5 cells/well. Normal serum, normal serum containing activated platelets and three different curcumin concentrations (2.5, 5 and 10 µM) + normal serum containing activated platelets were added to wells and cultured for 12 h. An inverted microscope was used to observe and photograph capillary tube formation, and Image J v.6.0 software (National Institutes of Health, Bethesda, MD, USA) was used to quantitatively analyse cavity formation length. Each group included three replicates. Five fields were selected for each well, and the experiment was repeated three times.
Transwell invasion assay.
Transwell chambers in a 24-well plate were used for the Transwell invasion assay. For each sample, the surface of the membrane was evenly spread with Dulbecco's modified Eagle's medium (DMEM)-diluted Matrigel containing a diluted growth factor (Matrigel:DMEM, 1:4, v/v) and maintained in an incubator (37˚C, 5% CO 2 ) for 30 min prior to cell seeding. Then 100 µl of INMEC suspension (1x10 5 /ml) in the logarithmic growth phase was inoculated into the upper chamber and 600 µl of serum free-DMEM was added. Each group was assigned three wells. Normal culture medium, activated platelets, activated platelets +2.5 µM curcumin, activated platelets +5 µM curcumin and activated platelets +10 µM curcumin were added to the wells and cultured for 24 h. Cells were stained with 0.1% crystal violet (Beyotime Institute of Biotechnology) at room temperature for 5 min, The chamber was then removed, medium discarded and samples were washed twice with PBS. Tweezers were used to place the filter membrane onto a slide plate, and five fields were randomly selected under an inverted light microscope to observe and count the number of migratory cells (magnification, x100).
Western blot analysis. INMECs were collected from the groups and the total proteins or nuclear proteins were extracted using a total protein extraction kit or nucleus protein kit respectively. The protein concentrations were quantified by bicinchoninic acid assay. In brief, 50 µg protein samples were loaded/lane to perform electrophoresis with 12% SDS-PAGE then transferred to polyvinylidene difluoride membranes. Following blocking of the membranes with 5% skimmed milk at 37˚C for 1 h, the membranes were incubated with primary antibodies (α-SMA, 1:1,000; collagen I, 1:1,000; E-cadherin, 1:2,000; VEGFR, 1:1,000; PI3K, 1:1,000; p-PI3K, 1:1,000; AKT, 1:1,000; p-AKT, 1:1,000; mTOR, 1:1,000; p-mTOR, 1:1,000; HIF-1α, 1:1,000; LamB1, 1:2,000 and GAPDH, 1:500). The samples were incubated overnight at 4˚C and washed thrice with PBS. Membranes were incubated with HRP-marked second antibody (1:2,000; cat. no. ab205718; Abcam, Cambridge, UK) at room temperature for 1 h. Enhanced chemiluminescence reagent was used to visualise protein bands and band intensity were analysed using Image J v6.0 software (National Institutes of Health). GAPDH was used as a reference in this experiment.
Immunofluorescence staining. INMECs were inoculated into 48-well plates, and the corresponding treatments were added for 12 h. Then cells were washed with PBS, fixed with 2% polyoxymethylene for 30 min and washed again with PBS (30 sec; three times) at room temperature. The cells were permeated with 1% Triton X-100 then 5% bovine serum albumin was used to block samples at room temperature for 1 h. HIF-1α antibody (1:1,000; cat. no. ab51608; Abcam) was added and samples were incubated overnight at 4˚C then washed with PBS. Fluorescein-conjugated secondary antibody (1:1,000; cat. no. ab205718) was added to samples at room temperature for 2 h then DAPI was used to stain the nuclei and buffered glycerol was added to mount samples. HIF-1α staining was observed under a laser confocal microscope (magnification, x100) following 1 h.
Statistical analysis. Data were presented as mean ± standard deviation. SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used for data analysis. A one-way analysis of variance with a post hoc Dunnett's t-test was used to assess differences amongst the groups. P<0.05 was considered to indicate statistical significance.
Results
Cell viability following treatment with different curcumin concentrations.
There were no significant differences in cell viability amongst the 0, 0.625, 1.25, 2.5, 5 and 10 µM curcumin concentration groups (P>0.05; Fig. 1 ). However, cell viability of the 20 and 40 µM curcumin concentration groups significantly decreased compared with the 0 µM curcumin concentration group (P<0.001; Fig. 1 ). The results demonstrated that the 0, 0.625, 1.25, 2.5, 5 and 10 µM curcumin concentrations were suitable for INMECs in this in vitro study.
VEGF concentration decreases with increasing curcumin concentration.
Compared with the control group, the VEGF concentration of the platelets group was significantly upregulated (P<0.001; Fig. 2 ), indicating that activated platelets stimulated INMECs to secrete VEGF. With curcumin supplementation, the VEGF concentrations of the different curcumin-treated groups were significantly suppressed compared with the platelets group (P<0.05; Fig. 2 ). Furthermore, there was a significant difference in terms of VEGF concentration amongst the different curcumin concentration-treated groups (Fig. 2) .
Branch point numbers decrease with increasing curcumin
concentrations. There was a significantly higher branch point number in the platelets group compared with the control group (P<0.05; Fig. 3 ), suggesting that activated platelets induced angiogenesis in INMECs. However, there were significantly fewer branch points in the curcumin-treated groups than in the platelets group (P<0.05; Fig. 3 ) with curcumin concentration exhibiting a dose-dependent association (P<0.05; Fig. 3 ).
Cell invasion decreases with increasing curcumin concentration.
Compared with the platelets group, the 5 µM (P<0.05; Fig. 4 ) and 10 µM (P<0.01; Fig. 4 ) curcumin-treated groups had significantly decreased cell invasion. These results suggested that 5 and 10 µM curcumin concentrations suppressed the number of migrated INMECs in vitro.
α-SMA, collagen I, E-cadherin and VEGFR protein expression levels following curcumin treatment. Compared with the control group, the platelets group exhibited significantly upregulated α-SMA, collagen I and E-cadherin protein expression levels (P<0.05; Fig. 5 ). However, α-SMA, collagen I and E-cadherin protein expression levels were significantly suppressed in a dose-dependent manner in the curcumin-treated groups compared with the platelets group (P<0.05; Fig. 5 ). There were no significant differences in VEGFR protein levels amongst the different groups (P>0.05; Fig. 5 ).
PI3K/AKT/mTOR pathway relative to HIF-1α protein expression levels following curcumin treatment.
There were no significant differences in PI3K, AKT and mTOR protein expression levels amongst the five groups (P>0.05; Fig. 6 ). The p-PI3K, p-AKT, p-mTOR and HIF-1α protein expression levels were significantly suppressed in the curcumin-treated groups, in a dose-dependent manner, compared with the platelets group (P<0.05; Fig. 6 ). These results suggested that curcumin affects HIF-1α by regulating phosphorylation of the PI3K/AKT/mTOR pathway.
HIF-1α and LamB1 protein expression levels in the nucleus following curcumin treatment.
Compared with the control group, the platelets group significantly upregulated HIF-1α protein expression levels in the nucleus (P<0.05; Fig. 7 ). Curcumin treatment significantly suppressed HIF-1α protein expression levels in the 5.0 and 10.0 µM curcumin-treated groups (P<0.05; Fig. 7 ). In addition, there was a significant difference between the 5 and 10 µM curcumin-treated groups (P<0.05; Fig. 7) .
HIF-1α protein nuclear translocation. The immunofluorescence staining results determined that HIF-1α protein expression levels increased following stimulation with activated platelets (Fig. 8) . By contrast, curcumin suppressed HIF-1α protein expression levels and decreased HIF-1α protein nuclear translocation in vitro (Fig. 8) .
Discussion
The most commonly used drugs for the treatment of CD include aminosalicylic acid, glucocorticoids, immunosuppressive agents, inflammatory transmitter inhibitors, targeted biological immunotherapy and antibiotics (11) . In the treatment of CD, traditional Chinese medicine has been proven to be multi-channel medicines and can be used for long-term treatment of patients, with fewer adverse events (12, 13) . During CD development, INMECs produce blood vessels induced by activated platelets (14-16). Curcumin is a traditional natural drug extract that exhibits anti-inflammatory, antitumour and immunoregulation properties (17) (18) (19) . However, the treatment effects of curcumin on CD remain unclear. Firstly, the present study evaluated the safety of curcumin on INMECs. MTT assay results demonstrated that curcumin concentrations below 20 µM did not cause significant toxicity. The effects and mechanisms of curcumin on angiogenesis and the invasion of INMECs induced by activated platelet stimulation were then investigated. The results demonstrated that VEGF concentration was significantly reduced, branch point number was decreased and number of migrated cells were decreased with curcumin treatment in a dose-dependent manner. Finally, the relative protein expression levels were investigated to determine the mechanism of action.
Previous studies demonstrated that α-SMA, collagen I, E-cadherin and VEGFR have key roles in cell migrahave key roles in cell migration (20) (21) (22) (23) (24) . The present study demonstrated that curcumin suppressed INMEC angiogenesis and invasion by regulating α-SMA, collagen I and E-cadherin protein expression levels. By contrast, curcumin did not have significant effects on VEGFR protein expression levels. α-SMA, collagen I and E-cadherin genes are downstream of the HIF-1α signalling pathway, therefore the upstream signalling pathway was investigated to determine the effects of curcumin in vitro.
PI3K/AKT/mTOR/HIF-1α pathway stimulation is a crucial component in cell angiogenesis and migration, and can induce α-SMA, collagen I and E-cadherin protein activation (25-30). The present study identified that curcumin affected phosphorylation of the PI3K/AKT/mTOR pathway; when suppressed, HIF-1α total and nuclear protein expression decreased. HIF-1α nuclear translocation is an essential part of the association between the PI3K/AKT/mTOR pathway and downstream genes (α-SMA, collagen I and E-cadherin). HIF-1α nuclear translocation was observed by immunofluorescence staining with the results demonstrating that HIF-1α nuclear translocation was inhibited by curcumin supplementation. In conclusion, curcumin was identified to have a dose-dependent inhibitory effect on INMEC angiogenesis and invasion induced by activated platelets, likely via inhibiting PI3K/AKT/mTOR pathway activation.
